Dyslipidemia - Pipeline Review, H2 2016 published by Global Markets Direct now available at Zursh

San Diego: Dyslipidemia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood.
Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood, such as genetic predisposition, diet, age and gender, and type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.
The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 19, 17, 15, 3, 45, 5 and 3, respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 14 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Dyslipidemia Overview
  3. Therapeutics Development
  4. Pipeline Products for Dyslipidemia - Overview
  5. Pipeline Products for Dyslipidemia - Comparative Analysis
  6. Dyslipidemia - Therapeutics under Development by Companies
  7. Dyslipidemia - Therapeutics under Investigation by Universities/Institutes
  8. Dyslipidemia Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Dyslipidemia - Products under Development by Companies
  13. Dyslipidemia - Products under Investigation by Universities/Institutes
  14. Dyslipidemia - Companies Involved in Therapeutics Development
Companies Involved:
  • Acasti Pharma Inc.
  • AFFiRiS AG
  • AstraZeneca Plc
  • BCWorld Pharm Co. Ltd.
  • BioRestorative Therapies, Inc.
  • Cadila Pharmaceuticals Limited
  • Cardax, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Debiopharm International SA
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • Gemphire Therapeutics Inc.
  • GlaxoSmithKline Plc
  • Golden Biotechnology Corp.
  • HanAll Biopharma Co., Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Huons Co., Ltd.
  • Hyundai Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • IPCA Laboratories Limited
  • Jeil Pharmaceutical Co., Ltd.
  • Lipicard Technologies Limited
  • Lipigon Pharmaceuticals AB
  • LipimetiX Development Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Matinas BioPharma Holdings, Inc.
  • Merck & Co., Inc.
  • Nimbus Therapeutics, LLC
  • Nippon Chemiphar Co., Ltd.
  • Omeros Corporation
  • Pfizer Inc.
  • Thetis Pharmaceuticals LLC
  • Torrent Pharmaceuticals Limited
Tweets From The Industry


Please find more about Dyslipidemia - Pipeline Review, H2 2016 at reports.zursh.com

Click on below items to see free updates about the topic covered.

Industry Updates

Click on below items to see free resources and reports about the topic covered.

Free Resources

Contact Information

Simon Sliman
Simon Sliman (write to Simon)
Research Manager
Zursh Inc. www.zursh.com | reports.zursh.com
Email: reports(at)zursh(dot)com
Lloyd Chambers
Lloyd Chambers (write to Lloyd)
Research Manager
Zursh Inc. www.zursh.com | reports.zursh.com
Email: reports(at)zursh(dot)com

Free Research Updates

Get Latest Updates Completely Free When New Research in Your Industry is Released

Free Research Updates

Get Latest Updates Completely Free When New Research in Your Industry is Released

*We Don't Spam